Tagrix (Osimertinib) 80 MG

Description

Tagrix (Osimertinib ) is the 1st and only drug of its kind approved by USFDA for the treatment of epidermal growth factor receptor (EGFR) positive Non- Small Cell Lung Cancer (NSCLC) patient with T790M mutation.

Tagrix 80 mg Tablets manufactured by Beacon consists of generic molecule which is use for the treatment of lung cancer. This molecule is marketed by Beacon with the brand name Tagrix 80 mg. Consumer needs to provide a prescription copy to buy anti-cancer & other medicines from Glareamed.

Therapeutic indications Of Tagrix 

This product indicate for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

DESCRIPTION

Product Features:

Product Name : Tagrix
Generic Name : Osimertinib
Formulation : Tablet
Available Pack Size : 30’s
Available Strengths : 40mg & 80mg
Categories : Oncology

Indications Of Osimertinib

Tagrix indicate for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) and detected by an FDA-approved test. This disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
*Take according to the doctor’s advice
Therapeutic Class
Cytotoxic Chemotherapy
Pharmacology

This generic product is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that binds to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion). This drug predominate in non-small cell lung cancer (NSCLC). Tumours follow the treatment with first-line EGFR-TKIs. As a third-generation tyrosine kinase inhibitor, this is specific for the gate-keeper T790M mutation. The Medicine increases ATP binding activity to EGFR and results in poor prognosis for late-stage disease.  The Capsule spare wild-type EGFR during the therapy. After reducing non-specific binding and limiting toxicity.
Dosage
The recommended dose of Capsule once a day until disease progression or unacceptable toxicity. This medicine can taken with or without food.
*Take according to the doctor’s advice

Interaction of Osimertinib

If concurrent use is unavoidable, increase with dosage to 160 mg daily. Process with a strong CYP3A inducer by coadministering . Resume at 80 mg 3 weeks after discontinuation of the strong CYP3A4 inducer.

Side Effects

Common side effects are Interstitial Lung Disease or Pneumonitis, QTc Interval Prolongation, Cardiomyopathy, Keratitis

Visit our another cancer related product here: